STOCK TITAN

10X Genomics, Inc. - TXG STOCK NEWS

Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.

10X Genomics, Inc. (TXG) drives innovation in life sciences through advanced single cell and spatial biology solutions. This news hub provides investors and researchers with essential updates about technological advancements, strategic partnerships, and financial developments shaping the future of biological research.

Access authoritative information on product launches, peer-reviewed study validations, and regulatory milestones. Our curated collection includes earnings reports, executive commentary, and analyses of how TXG's platforms enable breakthroughs in oncology, immunology, and neuroscience research.

Key updates cover instrument innovations, software enhancements, and collaborations with leading research organizations. Monitor progress in making high-resolution cellular analysis more accessible to academic institutions and biopharmaceutical developers worldwide.

Bookmark this page for streamlined access to verified TXG developments. Check regularly for insights into how the company continues redefining biological discovery through integrated hardware, consumables, and data analysis solutions.

Rhea-AI Summary
10x Genomics to report Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.98%
Tags
conferences earnings
-
Rhea-AI Summary
UPC denies second preliminary injunction request against NanoString Technologies, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.81%
Tags
none
-
Rhea-AI Summary
European Unified Patent Court issues preliminary injunction against NanoString for infringing EP 782 patent, preventing sales in 17 countries of the UPC. 10x Genomics intends to seek more than $30 million in damages for sales prior to trial in the US case. Trial for second US suit against NanoString scheduled for September 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
none
Rhea-AI Summary
10x Genomics announces new kit to expand capabilities of its Chromium Single Cell Gene Expression Flex assay for multiomic cellular profiling
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
-
Rhea-AI Summary
10x Genomics' technologies were used in a study that explains why immune checkpoint blockade is more effective for treating cancers that spread to the brain than for cancers that originate in the brain. The study analyzed resected glioblastoma and brain metastases from patients and found that brain metastases had higher T-cell infiltration into the tumor parenchyma. Researchers also identified an immune subpopulation correlated with better overall survival. The study suggests new combination immunotherapy strategies using blocking inhibitory receptors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
none
-
Rhea-AI Summary
10x Genomics, Inc. will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on September 12. The webcast of the chat will be available on the company's website for replay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
none
10X Genomics, Inc.

Nasdaq:TXG

TXG Rankings

TXG Stock Data

924.73M
106.05M
2.14%
96.93%
11.26%
Health Information Services
Laboratory Analytical Instruments
Link
United States
PLEASANTON